Association of Women SurgeonsRisk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review
Section snippets
Search strategy
The preferred reporting items for systematic reviews and meta-analyses statement was followed to perform the systematic review that included trials without any restrictions on publication date. The last search was carried out on January 16, 2016. A review of surgical management strategies for BRCA mutation carriers was performed by searching the electronic databases PubMed, OVID MEDLINE, and Scopus. The terms “risk reduction,” “risk reducing,” “prophylactic,” “BRCA1,” “BRCA2,” “BRCA,” and
Results
Our literature search for prophylactic or risk-reducing mastectomy in BRCA patients identified 1,902 articles through PubMed, OVID MEDLINE, and Scopus. After excluding case reports, reviews, comments, editorial, and letters and non-English publications, 1,085 records remained. After duplicates were removed, there were 495 records. A total of 483 records were excluded because they were not relevant to the review leaving 12 full-text articles assessed for eligibility. An additional 2 were
Breast cancer risk reduction
A total of 10 studies specifically described the incidence of breast cancers after bilateral risk-reducing mastectomies (BRRM).14, 15, 16, 17, 18, 19, 20, 21, 22, 23 They demonstrated a significant risk reduction in the incidence of breast cancer with BRRM ranging from 89.5% to 100% (Table 2). A total of 5 of these studies compared BRRM with surveillance15, 16, 18, 19, 20 and 5 only described the incidence of occult cancers at surgery and in follow-up after BRRM.14, 17, 21, 22, 23 Of the 10
Ovarian cancer risk reduction
A total of 8 studies had cancer occurrence as an outcome, including ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma.16, 24, 25, 26, 27, 28, 29, 30 Of all the studies, 6 compared surveillance to surgery,16, 24, 26, 28, 29, 30 (Table 3) whereas 2 reported the prevalence of occult cancers and risk of primary peritoneal carcinoma after RRBSO.25, 27
The 6 studies comparing RRBSO to surveillance reported a profound reduction in ovarian cancer risk, ranging from 72% to 88%.16, 23
Comments
This systematic review addresses the question of whether RRBSO and/or BRRM is beneficial for BRCA mutation carriers with respect to risk reduction and mortality. Primary studies of BRCA mutation carriers who have undergone BRRM in this review demonstrate a significant risk reduction in breast cancer incidence. The risk of breast cancer after BRRM is less than 3%, and the risk reduction appears to be equal in both BRCA1 and BRCA2 mutation carriers (Table 2).14, 15, 16, 17, 18, 19, 20, 21, 22, 23
Individualized decision making
With the increasing indications for genetic testing that are constantly changing,9 more women will be diagnosed with BRCA mutations. Currently, it is not feasible to personalize BRCA carriers' cancer risk based on the specific deleterious mutation. Instead, average risk among a group of carriers with a representative mix of mutations in the population must be calculated. One of the most comprehensive studies of BRCA1 and BRCA2 penetrance found that the mean cumulative cancer risks for mutation
Conclusions
In summary, our systematic review aimed to determine whether prophylactic surgery improves outcomes in unaffected BRCA carriers. The data presented here confirm both BRRM and RRBSO result in a reduction in both breast and ovarian cancers. Improvement in ovarian cancer–related and all-cause mortality was seen with RRBSO with moderate-quality data. However, this improvement was not seen with BRRM as the data were of low quality. Need for longer follow-up and heterogeneity in reporting contribute
References (42)
- et al.
Ten genes for inherited breast cancer
Cancer Cell
(2007) - et al.
Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer
Genet Med
(2015) - et al.
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis
Ann Oncol
(2013) - et al.
Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers
Am J Obstet Gynecol
(2013) - et al.
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers
Clin Breast Cancer
(2007) - et al.
Breast cancer statistics, 2013
Cancer J Clin
(2014) - et al.
Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes
Eur J Hum Genet
(2014) - et al.
Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application
Breast J
(2012) - et al.
Hereditary breast cancer: new genetic developments, new therapeutic avenues
Hum Genet
(2008) - et al.
Genetic testing by cancer site: breast
Cancer J
(2012)
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel
Cancer
Genetic/familial high-risk assessment: breast and ovarian (version 2.2016)
Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging
J Clin Oncol
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study
Br J Cancer
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
BMJ
Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers
J Natl Cancer Inst
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group
J Clin Oncol
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality
JAMA
Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer
Ann Surg
Breast cancer after bilateral risk-reducing mastectomy
Clin Genet
Cited by (159)
BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits
2024, American Journal of SurgeryInfluence of family history on penetrance of hereditary cancers in a population setting
2023, eClinicalMedicineQuality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis
2023, American Journal of Obstetrics and Gynecology
The authors declare no conflicts of interest.